Search

Your search keyword '"Knorr, David"' showing total 298 results
Start Over Author "Knorr, David"
298 results on '"Knorr, David"'

1. Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia

Author

Knorr, Katherine, Rahman, Jahan, Erickson, Caroline, Wang, Eric, Monetti, Mara, Li, Zhuoning, Ortiz-Pacheco, Juliana, Jones, Andrew, Lu, Sydney X., Stanley, Robert F., Baez, Maria, Fox, Nina, Castro, Cynthia, Marino, Alessandra E., Jiang, Caroline, Penson, Alex, Hogg, Simon J., Mi, Xiaoli, Nakajima, Hideaki, Kunimoto, Hiroyoshi, Nishimura, Koutarou, Inoue, Daichi, Greenbaum, Benjamin, Knorr, David, Ravetch, Jeffrey, and Abdel-Wahab, Omar

Published
2023
Full Text
View/download PDF

3. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine

Author

Herati, Ramin Sedaghat, Knorr, David A., Vella, Laura A., Silva, Luisa Victoria, Chilukuri, Lakshmi, Apostolidis, Sokratis A., Huang, Alexander C., Muselman, Alexander, Manne, Sasikanth, Kuthuru, Oliva, Staupe, Ryan P., Adamski, Sharon A., Kannan, Senthil, Kurupati, Raj K., Ertl, Hildegund C. J., Wong, Jeffrey L., Bournazos, Stylianos, McGettigan, Suzanne, Schuchter, Lynn M., Kotecha, Ritesh R., Funt, Samuel A., Voss, Martin H., Motzer, Robert J., Lee, Chung-Han, Bajorin, Dean F., Mitchell, Tara C., Ravetch, Jeffrey V., and Wherry, E. John

Published
2022
Full Text
View/download PDF

4. MP16-17 PHASE I STUDY OF INTRAVESICAL FC-OPTIMIZED ANTI-CD40 AGONIST ANTIBODY 2141-V11 FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)

Author

Bochner, Bernard H., primary, Alam, Muneeb, additional, Osorio, Juan C., additional, Wong, Jeffrey L., additional, Knorr, David, additional, Blanchard, Lucas, additional, Angulo-Lozano, Juan, additional, Whiting, Karissa, additional, Seshan, Venkatraman E., additional, Donahue, Timothy, additional, Cha, Eugene, additional, Goh, Alvin, additional, Smith, Robert, additional, Dalbagni, Guido, additional, Hernandez, Christian, additional, McCarter, Melissa, additional, Pietzak, Eugene J., additional, Rosenberg, Jonathan E., additional, and Ravetch, Jeffrey V., additional

Published
2024
Full Text
View/download PDF

5. Supplementary Figure 2 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

Author

Knorr, David A., primary, Blanchard, Lucas, primary, Leidner, Rom S., primary, Jensen, Shawn M., primary, Meng, Ryan, primary, Jones, Andrew, primary, Ballesteros-Merino, Carmen, primary, Bell, Richard B., primary, Baez, Maria, primary, Marino, Alessandra, primary, Sprott, David, primary, Bifulco, Carlo B., primary, Piening, Brian, primary, Dahan, Rony, primary, Osorio, Juan C., primary, Fox, Bernard A., primary, and Ravetch, Jeffrey V., primary

Published
2024
Full Text
View/download PDF

6. Supplementary Figure 4 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

Author

Knorr, David A., primary, Blanchard, Lucas, primary, Leidner, Rom S., primary, Jensen, Shawn M., primary, Meng, Ryan, primary, Jones, Andrew, primary, Ballesteros-Merino, Carmen, primary, Bell, Richard B., primary, Baez, Maria, primary, Marino, Alessandra, primary, Sprott, David, primary, Bifulco, Carlo B., primary, Piening, Brian, primary, Dahan, Rony, primary, Osorio, Juan C., primary, Fox, Bernard A., primary, and Ravetch, Jeffrey V., primary

Published
2024
Full Text
View/download PDF

7. Supplementary Figure 3 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

Author

Knorr, David A., primary, Blanchard, Lucas, primary, Leidner, Rom S., primary, Jensen, Shawn M., primary, Meng, Ryan, primary, Jones, Andrew, primary, Ballesteros-Merino, Carmen, primary, Bell, Richard B., primary, Baez, Maria, primary, Marino, Alessandra, primary, Sprott, David, primary, Bifulco, Carlo B., primary, Piening, Brian, primary, Dahan, Rony, primary, Osorio, Juan C., primary, Fox, Bernard A., primary, and Ravetch, Jeffrey V., primary

Published
2024
Full Text
View/download PDF

8. Supplementary Table 2 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

Author

Knorr, David A., primary, Blanchard, Lucas, primary, Leidner, Rom S., primary, Jensen, Shawn M., primary, Meng, Ryan, primary, Jones, Andrew, primary, Ballesteros-Merino, Carmen, primary, Bell, Richard B., primary, Baez, Maria, primary, Marino, Alessandra, primary, Sprott, David, primary, Bifulco, Carlo B., primary, Piening, Brian, primary, Dahan, Rony, primary, Osorio, Juan C., primary, Fox, Bernard A., primary, and Ravetch, Jeffrey V., primary

Published
2024
Full Text
View/download PDF

9. Data from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

Author

Knorr, David A., primary, Blanchard, Lucas, primary, Leidner, Rom S., primary, Jensen, Shawn M., primary, Meng, Ryan, primary, Jones, Andrew, primary, Ballesteros-Merino, Carmen, primary, Bell, Richard B., primary, Baez, Maria, primary, Marino, Alessandra, primary, Sprott, David, primary, Bifulco, Carlo B., primary, Piening, Brian, primary, Dahan, Rony, primary, Osorio, Juan C., primary, Fox, Bernard A., primary, and Ravetch, Jeffrey V., primary

Published
2024
Full Text
View/download PDF

10. Supplementary Table 3 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

Author

Knorr, David A., primary, Blanchard, Lucas, primary, Leidner, Rom S., primary, Jensen, Shawn M., primary, Meng, Ryan, primary, Jones, Andrew, primary, Ballesteros-Merino, Carmen, primary, Bell, Richard B., primary, Baez, Maria, primary, Marino, Alessandra, primary, Sprott, David, primary, Bifulco, Carlo B., primary, Piening, Brian, primary, Dahan, Rony, primary, Osorio, Juan C., primary, Fox, Bernard A., primary, and Ravetch, Jeffrey V., primary

Published
2024
Full Text
View/download PDF

11. Supplementary Figure Legends from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

Author

Knorr, David A., primary, Blanchard, Lucas, primary, Leidner, Rom S., primary, Jensen, Shawn M., primary, Meng, Ryan, primary, Jones, Andrew, primary, Ballesteros-Merino, Carmen, primary, Bell, Richard B., primary, Baez, Maria, primary, Marino, Alessandra, primary, Sprott, David, primary, Bifulco, Carlo B., primary, Piening, Brian, primary, Dahan, Rony, primary, Osorio, Juan C., primary, Fox, Bernard A., primary, and Ravetch, Jeffrey V., primary

Published
2024
Full Text
View/download PDF

12. Supplementary Table 1 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

Author

Knorr, David A., primary, Blanchard, Lucas, primary, Leidner, Rom S., primary, Jensen, Shawn M., primary, Meng, Ryan, primary, Jones, Andrew, primary, Ballesteros-Merino, Carmen, primary, Bell, Richard B., primary, Baez, Maria, primary, Marino, Alessandra, primary, Sprott, David, primary, Bifulco, Carlo B., primary, Piening, Brian, primary, Dahan, Rony, primary, Osorio, Juan C., primary, Fox, Bernard A., primary, and Ravetch, Jeffrey V., primary

Published
2024
Full Text
View/download PDF

13. Supplementary Figure 1 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

Author

Knorr, David A., primary, Blanchard, Lucas, primary, Leidner, Rom S., primary, Jensen, Shawn M., primary, Meng, Ryan, primary, Jones, Andrew, primary, Ballesteros-Merino, Carmen, primary, Bell, Richard B., primary, Baez, Maria, primary, Marino, Alessandra, primary, Sprott, David, primary, Bifulco, Carlo B., primary, Piening, Brian, primary, Dahan, Rony, primary, Osorio, Juan C., primary, Fox, Bernard A., primary, and Ravetch, Jeffrey V., primary

Published
2024
Full Text
View/download PDF

14. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity

Author

Lu, Sydney X., De Neef, Emma, Thomas, James D., Sabio, Erich, Rousseau, Benoit, Gigoux, Mathieu, Knorr, David A., Greenbaum, Benjamin, Elhanati, Yuval, Hogg, Simon J., Chow, Andrew, Ghosh, Arnab, Xie, Abigail, Zamarin, Dmitriy, Cui, Daniel, Erickson, Caroline, Singer, Michael, Cho, Hana, Wang, Eric, Lu, Bin, Durham, Benjamin H., Shah, Harshal, Chowell, Diego, Gabel, Austin M., Shen, Yudao, Liu, Jing, Jin, Jian, Rhodes, Matthew C., Taylor, Richard E., Molina, Henrik, Wolchok, Jedd D., Merghoub, Taha, Diaz, Luis A., Jr., Abdel-Wahab, Omar, and Bradley, Robert K.

Published
2021
Full Text
View/download PDF

15. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Author

Roeker, Lindsey E., Knorr, David A., Thompson, Meghan C., Nivar, Mariely, Lebowitz, Sonia, Peters, Nicole, Deonarine, Jr, Isaac, Momotaj, Saddia, Sharan, Saumya, Chanlatte, Vanessa, Hampton, Bianca, Butala, Liana, Amato, Lindsay, Richford, Angela, Lunkenheimer, Jessica, Battiato, Kristen, Laudati, Carissa, and Mato, Anthony R.

Published
2021
Full Text
View/download PDF

16. FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment

Author

Knorr, David A., primary, Blanchard, Lucas, additional, Leidner, Rom S., additional, Jensen, Shawn M., additional, Meng, Ryan, additional, Jones, Andrew, additional, Ballesteros-Merino, Carmen, additional, Bell, Richard B., additional, Baez, Maria, additional, Marino, Alessandra, additional, Sprott, David, additional, Bifulco, Carlo B., additional, Piening, Brian, additional, Dahan, Rony, additional, Osorio, Juan C., additional, Fox, Bernard A., additional, and Ravetch, Jeffrey V., additional

Published
2023
Full Text
View/download PDF

18. Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo.

Author

Ni, Zhenya, Knorr, David A, Bendzick, Laura, Allred, Jeremy, and Kaufman, Dan S

Subjects
Killer Cells, Natural, Cell Line, Animals, Humans, Mice, HIV-1, HIV Infections, Antigens, CD4, Recombinant Fusion Proteins, Stem Cell Transplantation, Gene Expression Regulation, Embryonic Stem Cells, Induced Pluripotent Stem Cells, HIV-1 infection inhibition, Human embryonic stem cells, In vitro, In vivo, Induced pluripotent stem cells, Natural killer cells, CD4 Antigens, Killer Cells, Natural, Antigens, CD4, Biological Sciences, Technology, Medical and Health Sciences, Immunology
Abstract

Cell-based immunotherapy has been gaining interest as an improved means to treat human immunodeficiency virus (HIV)/AIDS. Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) could become a potential resource. Our previous studies have shown hESC and iPSC-derived natural killer (NK) cells can inhibit HIV-infected targets in vitro. Here, we advance those studies by expressing a HIV chimeric receptor combining the extracellular portion of CD4 to the CD3ζ intracellular signaling chain. We hypothesized that expression of this CD4ζ receptor would more efficiently direct hESC- and iPSC-derived NK cells to target HIV-infected cells. In vitro studies showed the CD4ζ expressing hESC- and iPSC-NK cells inhibited HIV replication in CD4+ T-cells more efficiently than their unmodified counterparts. We then evaluated CD4ζ expressing hESC (CD4ζ-hESC)- and iPSC-NK cells in vivo anti-HIV activity using a humanized mouse model. We demonstrated significant suppression of HIV replication in mice treated with both CD4ζ-modified and -unmodified hESC-/iPSC-NK cells compared with control mice. However, we did not observe significantly increased efficacy of CD4ζ expression in suppression of HIV infection. These studies indicate that hESC/iPSC-based immunotherapy can be used as a unique resource to target HIV/AIDS.

Published
2014

22. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model

Author

Geller, Melissa A, Knorr, David A, Hermanson, David A, Pribyl, Lee, Bendzick, Laura, Mccullar, Valarie, Miller, Jeffrey S, and Kaufman, Dan S

Subjects
Cancer, Rare Diseases, Ovarian Cancer, Orphan Drug, Biotechnology, 2.1 Biological and endogenous factors, Aetiology, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Adenocarcinoma, Animals, Antigens, Differentiation, Cancer Vaccines, Cell Proliferation, Cell Survival, Cytotoxicity, Immunologic, Female, Humans, Immunotherapy, Adoptive, Injections, Intraperitoneal, Interleukin-2, K562 Cells, Killer Cells, Natural, Lymphocyte Activation, Mice, Mice, Inbred NOD, Ovarian Neoplasms, Peritoneal Cavity, Recurrence, Tumor Burden, Xenograft Model Antitumor Assays, bioluminescent imaging, immunotherapy, natural killer (NK) cells, ovarian cancer, Clinical Sciences, Immunology
Abstract

Background aimsThere is an urgent need for novel therapeutic strategies for relapsed ovarian cancer. Dramatic clinical anti-tumor effects have been observed with interleukin (IL)-2 activated natural killer (NK) cells; however, intravenous delivery of NK cells in patients with ovarian cancer has not been successful in ameliorating disease. We investigated in vivo engraftment of intraperitoneally (IP) delivered NK cells in an ovarian cancer xenograft model to determine if delivery mode can affect tumor cell killing and circumvent lack of NK cell expansion.MethodsAn ovarian cancer xenograft mouse model was established to evaluate efficacy of IP-delivered NK cells. Tumor burden was monitored by bioluminescent imaging of luciferase-expressing ovarian cancer cells. NK cell persistence, tumor burden and NK cell trafficking were evaluated. Transplanted NK cells were evaluated by flow cytometry and cytotoxicity assays.ResultsIP delivery of human NK cells plus cytokines led to high levels of circulating NK and was effective in clearing intraperitoneal ovarian cancer burden in xenografted mice. NK cells remained within the peritoneal cavity 54 days after injection and had markers of maturation. Additionally, surviving NK cells were able to kill ovarian cancer cells at a rate similar to pre-infusion levels, supporting that in vivo functionality of human NK cells can be maintained after IP infusion.ConclusionsIP delivery of NK cells leads to stable engraftment and antitumor response in an ovarian cancer xenograft model. These data support further pre-clinical and clinical evaluation of IP delivery of allogeneic NK cells in ovarian cancer.

Published
2013

23. Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs).

Author

Bock, Allison M, Knorr, David, and Kaufman, Dan S

Subjects
Killer Cells, Natural, Pluripotent Stem Cells, Humans, Cytological Techniques, Cell Differentiation, Embryonic Stem Cells, Stem Cell Biology, Issue 74, Bioengineering, Biomedical Engineering, Medicine, Physiology, Anatomy, Cellular Biology, Molecular Biology, Biochemistry, Hematology, ESCs, ES Cells, Hematopoietic Stem Cells, HSC, Induced Pluripotent Stem Cells, iPSCs, Luciferases, Firefly, Immunotherapy, Adoptive, stem cells, differentiation, NK cells, in vivo imaging, fluorescent imaging, turboFP650, FACS, cell culture, Killer Cells, Natural, Biochemistry and Cell Biology, Psychology, Cognitive Sciences
Abstract

We present a method for deriving natural killer (NK) cells from undifferentiated hESCs and iPSCs using a feeder-free approach. This method gives rise to high levels of NK cells after 4 weeks culture and can undergo further 2-log expansion with artificial antigen presenting cells. hESC- and iPSC-derived NK cells developed in this system have a mature phenotype and function. The production of large numbers of genetically modifiable NK cells is applicable for both basic mechanistic as well as anti-tumor studies. Expression of firefly luciferase in hESC-derived NK cells allows a non-invasive approach to follow NK cell engraftment, distribution, and function. We also describe a dual-imaging scheme that allows separate monitoring of two different cell populations to more distinctly characterize their interactions in vivo. This method of derivation, expansion, and dual in vivo imaging provides a reliable approach for producing NK cells and their evaluation which is necessary to improve current NK cell adoptive therapies.

Published
2013

26. Data from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Author

Tamari, Roni, primary, Politikos, Ioannis, primary, Knorr, David A., primary, Vardhana, Santosha A., primary, Young, Jennifer C., primary, Marcello, LeeAnn T., primary, Doddi, Sital, primary, Devlin, Sean M., primary, Ramanathan, Lakshmi V., primary, Pessin, Melissa S., primary, Dunn, Erica, primary, Palazzo, Meighan, primary, Bravo, Christina D., primary, Papanicolaou, Genovefa A., primary, Kamboj, Mini, primary, Perales, Miguel Angel, primary, Chung, David J., primary, and Shah, Gunjan L., primary

Published
2023
Full Text
View/download PDF

27. Supplemental Table 3A&3B from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Author

Tamari, Roni, primary, Politikos, Ioannis, primary, Knorr, David A., primary, Vardhana, Santosha A., primary, Young, Jennifer C., primary, Marcello, LeeAnn T., primary, Doddi, Sital, primary, Devlin, Sean M., primary, Ramanathan, Lakshmi V., primary, Pessin, Melissa S., primary, Dunn, Erica, primary, Palazzo, Meighan, primary, Bravo, Christina D., primary, Papanicolaou, Genovefa A., primary, Kamboj, Mini, primary, Perales, Miguel Angel, primary, Chung, David J., primary, and Shah, Gunjan L., primary

Published
2023
Full Text
View/download PDF

28. Supplemental Table 1 from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Author

Tamari, Roni, primary, Politikos, Ioannis, primary, Knorr, David A., primary, Vardhana, Santosha A., primary, Young, Jennifer C., primary, Marcello, LeeAnn T., primary, Doddi, Sital, primary, Devlin, Sean M., primary, Ramanathan, Lakshmi V., primary, Pessin, Melissa S., primary, Dunn, Erica, primary, Palazzo, Meighan, primary, Bravo, Christina D., primary, Papanicolaou, Genovefa A., primary, Kamboj, Mini, primary, Perales, Miguel Angel, primary, Chung, David J., primary, and Shah, Gunjan L., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table and Figures from Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

Author

Chung, David J., primary, Shah, Gunjan L., primary, Devlin, Sean M., primary, Ramanathan, Lakshmi V., primary, Doddi, Sital, primary, Pessin, Melissa S., primary, Hoover, Elizabeth, primary, Marcello, LeeAnn T., primary, Young, Jennifer C., primary, Boutemine, Sawsan R., primary, Serrano, Edith, primary, Sharan, Saumya, primary, Momotaj, Saddia, primary, Margetich, Lauren, primary, Bravo, Christina D., primary, Papanicolaou, Genovefa A., primary, Kamboj, Mini, primary, Mato, Anthony R., primary, Roeker, Lindsey E., primary, Hultcrantz, Malin, primary, Mailankody, Sham, primary, Lesokhin, Alexander M., primary, Vardhana, Santosha A., primary, and Knorr, David A., primary

Published
2023
Full Text
View/download PDF

30. Data from Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

Author

Chung, David J., primary, Shah, Gunjan L., primary, Devlin, Sean M., primary, Ramanathan, Lakshmi V., primary, Doddi, Sital, primary, Pessin, Melissa S., primary, Hoover, Elizabeth, primary, Marcello, LeeAnn T., primary, Young, Jennifer C., primary, Boutemine, Sawsan R., primary, Serrano, Edith, primary, Sharan, Saumya, primary, Momotaj, Saddia, primary, Margetich, Lauren, primary, Bravo, Christina D., primary, Papanicolaou, Genovefa A., primary, Kamboj, Mini, primary, Mato, Anthony R., primary, Roeker, Lindsey E., primary, Hultcrantz, Malin, primary, Mailankody, Sham, primary, Lesokhin, Alexander M., primary, Vardhana, Santosha A., primary, and Knorr, David A., primary

Published
2023
Full Text
View/download PDF

31. Supplemental Table 2A&2B from Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Author

Tamari, Roni, primary, Politikos, Ioannis, primary, Knorr, David A., primary, Vardhana, Santosha A., primary, Young, Jennifer C., primary, Marcello, LeeAnn T., primary, Doddi, Sital, primary, Devlin, Sean M., primary, Ramanathan, Lakshmi V., primary, Pessin, Melissa S., primary, Dunn, Erica, primary, Palazzo, Meighan, primary, Bravo, Christina D., primary, Papanicolaou, Genovefa A., primary, Kamboj, Mini, primary, Perales, Miguel Angel, primary, Chung, David J., primary, and Shah, Gunjan L., primary

Published
2023
Full Text
View/download PDF

32. Abstract 5742: Pharmacologic modulation of RNA splicing enhances anti-tumor immunity

Author

Thomas, James D., primary, Lu, Sydney X., additional, De Neef, Emma, additional, Sabio, Erich, additional, Rousseau, Benoit, additional, Gigoux, Mathieu, additional, Knorr, David A., additional, Greenbaum, Benjamin, additional, Elhanati, Yuval, additional, Hogg, Simon J., additional, Chow, Andrew, additional, Ghosh, Arnab, additional, Xie, Abigail, additional, Zamarin, Dmitriy, additional, Cui, Daniel, additional, Erickson, Caroline, additional, Singer, Michael, additional, Cho, Hana, additional, Wang, Eric, additional, Lu, Bin, additional, Durham, Benjamin H., additional, Shah, Harshal, additional, Chowell, Diego, additional, Gabel, Austin M., additional, Shen, Yudao, additional, Liu, Jing, additional, Jin, Jian, additional, Rhodes, Matthew C., additional, Taylor, Richard E., additional, Molina, Henrik, additional, Wolchok, Jedd D., additional, Merghoub, Taha, additional, Jr, Luis A. Diaz, additional, Abdel-Wahab, Omar, additional, and Bradley, Robert K., additional

Published
2023
Full Text
View/download PDF

34. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models

Author

Parker, Scott, primary, McDowall, Charlotte, additional, Sanchez-Perez, Luis, additional, Osorio, Cristina, additional, Duncker, Patrick C., additional, Briley, Aaron, additional, Swartz, Adam M., additional, Herndon, James E., additional, Yu, Yen-Rei A., additional, McLendon, Roger E., additional, Tedder, Thomas F., additional, Desjardins, Annick, additional, Ashley, David M., additional, Gunn, Michael Dee, additional, Enterline, David S., additional, Knorr, David A., additional, Pastan, Ira H., additional, Nair, Smita K., additional, Bigner, Darell D., additional, and Chandramohan, Vidyalakshmi, additional

Published
2023
Full Text
View/download PDF

35. FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies

Author

Knorr, David, primary, Leidner, Rom, additional, Jensen, Shawn, additional, Meng, Ryan, additional, Jones, Andrew, additional, Ballesteros-Merino, Carmen, additional, Bell, R. Bryan, additional, Baez, Maria, additional, Sprott, David, additional, Bifulco, Carlo, additional, Piening, Brian, additional, Dahan, Rony, additional, Fox, Bernard A., additional, and Ravetch, Jeffrey, additional

Published
2023
Full Text
View/download PDF

37. Systematic Evaluation of AML-Associated Antigens Identifies Novel Anti-U5 snRNP200 Therapeutic Antibodies for the Treatment of AML

Author

Knorr, Katherine, primary, Erickson, Caroline, additional, Wang, Eric, additional, Rahman, Jahan, additional, Mi, Xiaoli, additional, Lu, Sydney, additional, Fox, Nina, additional, Penson, Alex, additional, Hogg, Simon, additional, Stanley, Robert, additional, Inoue, Daichi, additional, Knorr, David, additional, Ravetch, Jeffrey, additional, and Abdel-Wahab, Omar, additional

Published
2022
Full Text
View/download PDF

38. CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS)

Author

Desjardins, Annick, primary, Chandramohan, Vidya, additional, Landi, Daniel, additional, Peters, Katherine B, additional, Johnson, Margaret, additional, Khasraw, Mustafa, additional, Low, Justin, additional, Threatt, Stevie, additional, Bullock, Chevelle, additional, II, James E Herndon, additional, Lipp, Eric S, additional, Sampson, John, additional, Friedman, Allan, additional, Friedman, Henry S, additional, Ashley, David, additional, Knorr, David, additional, Ravetch, Jeffrey, additional, and Bigner, Darell, additional

Published
2022
Full Text
View/download PDF

39. Phase I study of intravesical anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) therapy.

Author

Wong, Jeffrey L., primary, Knorr, David, additional, Whiting, Karissa, additional, Seshan, Venkatraman E., additional, Pietzak, Eugene J., additional, Donahue, Timothy F., additional, Cha, Eugene K., additional, Goh, Alvin C., additional, Smith, Robert, additional, Dalbagni, Guido, additional, McGill, Marlena, additional, Hernandez, Christian, additional, McCarter, Melissa, additional, Rosenberg, Jonathan E., additional, and Bochner, Bernard H., additional

Published
2022
Full Text
View/download PDF

40. A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).

Author

Desjardins, Annick, primary, Chandramohan, Vidyalakshmi, additional, Landi, Daniel B, additional, Johnson, Margaret O., additional, Khasraw, Mustafa, additional, Peters, Katherine B., additional, Low, Justin, additional, Herndon, James Emmett, additional, Threatt, Stevie, additional, Bullock, Chevelle A., additional, Lipp, Eric S., additional, Sampson, John H., additional, Friedman, Allan H., additional, Friedman, Henry S., additional, Ashley, David M., additional, Knorr, David, additional, and Bigner, Darell D., additional

Published
2022
Full Text
View/download PDF

46. Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines

Author

Tamari, Roni, primary, Politikos, Ioannis, additional, Knorr, David, additional, Vardhana, Santosha, additional, Young, Jennifer, additional, Marcello, Leeann, additional, Doddi, Sital, additional, Devlin, Sean M, additional, Ramanathan, Lakshmi, additional, Pessin, Melissa S., additional, Dunn, Erica, additional, Palazzo, Meighan A., additional, Bravo, Christina, additional, Papanicolaou, Genovefa A., additional, Kamboj, Mini, additional, Perales, Miguel-Angel, additional, Chung, David J., additional, and Shah, Gunjan L, additional

Published
2021
Full Text
View/download PDF

48. Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Author

Tamari, Roni, primary, Politikos, Ioannis, additional, Knorr, David A., additional, Vardhana, Santosha A., additional, Young, Jennifer C., additional, Marcello, LeeAnn T., additional, Doddi, Sital, additional, Devlin, Sean M., additional, Ramanathan, Lakshmi V., additional, Pessin, Melissa S., additional, Dunn, Erica, additional, Palazzo, Meighan, additional, Bravo, Christina D., additional, Papanicolaou, Genovefa A., additional, Kamboj, Mini, additional, Perales, Miguel Angel, additional, Chung, David J., additional, and Shah, Gunjan L., additional

Published
2021
Full Text
View/download PDF

49. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

Author

Chung, David J., primary, Shah, Gunjan L., additional, Devlin, Sean M., additional, Ramanathan, Lakshmi V., additional, Doddi, Sital, additional, Pessin, Melissa S., additional, Hoover, Elizabeth, additional, Marcello, LeeAnn T., additional, Young, Jennifer C., additional, Boutemine, Sawsan R., additional, Serrano, Edith, additional, Sharan, Saumya, additional, Momotaj, Saddia, additional, Margetich, Lauren, additional, Bravo, Christina D., additional, Papanicolaou, Genovefa A., additional, Kamboj, Mini, additional, Mato, Anthony R., additional, Roeker, Lindsey E., additional, Hultcrantz, Malin, additional, Mailankody, Sham, additional, Lesokhin, Alexander M., additional, Vardhana, Santosha A., additional, and Knorr, David A., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results